Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04080180 · ClinicalTrials.gov registry record · NA

SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence

A NA study of Opioid Use Disorder, sponsored by Karen Derefinko, PhD.

Completed
Registry status
NA
Development phase
332
Enrollment target
1
Study location

NCT04080180 is a NA study of Opioid Use Disorder that has completed, run by Karen Derefinko, PhD. The registered enrollment target is 332 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04080180, a NA study of Opioid Use Disorder, has completed, sponsored by Karen Derefinko, PhD.

COMPLETED
Registry status
NA
Development phase
332 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the effectiveness of two different interventions for medication-assisted treatment (MAT) adherence: Contingency Management (CM) and Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM).

Conditions Studied

Interventions

  • BEHAVIORAL Contingency Management
  • BEHAVIORAL Brief Motivational Interviewing + Substance Free Activities + Mindfulness

Study Locations (1)

Tennessee

  • University of Tennessee Health Science Center - Memphis

Trial Details

FieldValue
Enrollment Target 332 participants
Start Date 2022-02-01
Est. Completion 2025-02-01
Phase NA

Sponsor

Karen Derefinko, PhD

4 total trials

What the Registry Record Tells You About NCT04080180

The ClinicalTrials.gov registry entry for NCT04080180 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (93% lower). The listed sponsor is Karen Derefinko, PhD, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Contingency Management is the first listed.

NCT04080180 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT04080180 about?

NCT04080180 is a clinical study titled "SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence". The purpose of this study is to compare the effectiveness of two different interventions for medication-assisted treatment (MAT) adherence: Contingency Management (CM) and Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM).

What is the current status of trial NCT04080180?

This trial is currently completed. It is a NA study. The enrollment target is 332 participants. The study started on 2022-02-01. Estimated completion is 2025-02-01.

What conditions does trial NCT04080180 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT04080180?

The interventions under investigation include: Contingency Management (BEHAVIORAL), Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BEHAVIORAL).

Who is sponsoring clinical trial NCT04080180?

This trial is sponsored by Karen Derefinko, PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04080180 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.